Approval Status
Approved August 1999

Treatment for


Raplon (rapacuronium bromide) has been approved as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures. Raplon was proven in studies to be an effective alternative to succinylcholine with a rapid onset and a short duration of action with the recommended dose.

Raplon is the first and only nondepolarizing neuromuscular blocking agent (NMBA) that combines both rapid onset with short duration for tracheal intubations and many short procedures including appendectomy, tonsillectomy, cystectomy, tubal ligation, and Cesarean section.

Raplon Drug Information

The Raplon drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top